Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer

Scandinavian Journal of Urology

Volumn 49, Issue 6, 2015, Pages 453-462

  Sherif, Amir ^a   Hasan, Mudhar N ^b   Radecka, Eva ^c   Rodriguez, Alvaro Lozano ^d   Shabo, Sarab ^e   Karlsson, Mona ^c   Schumacher, Martin C ^f   Marits, Per ^c   Winqvist, Ola ^c  

^a UMEÅ UNIVERSITY   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^e Mälarsjukhuset Hospital   (Sweden)

^f KLINIK HIRSLANDEN   (Switzerland)

Author keywords

Adoptive cellular immunotherapy; sentinel lymph node biopsy; urinary bladder neoplasms

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT RESPONSE;

EID: 84947577809     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2015.1059880     Document Type: Article

References (32)

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289-93.
2. Holmäng S, Hedelin H, Anderström C, Johansson SL. Long-term followup of all patients with muscle-invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol 1997;158:389-92.
3. Prout GR Jr, Griffin PP, Shipley WU. Bladder carcinoma as a systemic disease. Cancer 1979;43:2532-9.
4. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006;24:296-304.
5. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-66.
6. Sherif A, De La Torre M, Malmstrom PU, Thorn M. Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer. J Urol 2001;166:812-15.
7. Liedberg F, Chebil G, Davidsson T, Gudjonsson S, Månsson W. Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. J Urol 2006;175:84-8.
8. Sherif A, Garske U, de La Torre M, Thörn M. Hybrid SPECTCT-an additional technique for sentinel node detection of patients with invasive bladder cancer. Eur Urol 2006;50:83-91.
9. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
10. Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993;150:1018-23.
11. Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J Immunother 2008;31:34-42.
12. Marits P, Karlsson M, Sherif A, Garske U, Thörn M, Winqvist O. Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol 2006;49:59-70.
13. Dahl K, Karlsson M, Marits P, Hoffstedt A, Winqvist O, Thörn M. Metinel node - the first lymph node draining a metastasis-contains tumor-reactive lymphocytes. Ann Surg Oncol 2008;15:1454-63.
14. Karlsson M, Marits P, Dahl K, Dagöö T, Enerbäck S, Thörn M, et al. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol 2010;17:1747-57.
15. Sherif A, Hasan MN, Marits P, Karlsson M, Winqvist O, Thörn M. Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept. Eur Urol 2010;58:105-11.
16. Antony PA, Piccirillo CA, Akpinarli A Finkelstein SE, Speiss PJ, Surman DR, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T-helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591-601.
17. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005;434:88-93.
18. Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000;164:562-5.
19. Marits P, Karlsson M, Dahl K Larsson P, Wanders A, Thörn M, et al. Sentinel node lymphocytes: tumor reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer 2006;94:1478-84.
20. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18.
21. Advanced Bladder Cancer Meta-analysis Collaboration (ABC). Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48:202-6.
22. Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, et al. Nordic Urothelial Cancer Group. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004;45:297-303.
23. Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullen A, Nilsson S, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 2012;61:1229-38.
24. Wallmeroth A, Wagner U, Moch H, Gasser TC, Sauter G, Mihatsch MJ. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): an autopsy study on 367 patients. Urol Int 1999;62:69-75.
25. Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 2010;57:641-7.
26. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
27. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer Immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344: 641-5.
28. Mishra A, Shiozawa Y, Pienta KJ, Taichman RS. Homing of cancer cells to the bone. Cancer Microenviron 2011;4:221-35.
29. Wierda D, Pazdernik TL. Toxicity of platinum complexes on hemopoietic precursor cells. J Pharmacol Exp Ther 1979;211:531-8.
30. Huang X, Chen YT, Song HZ, Chun Huang GC, Chen LB. Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol 2011;17: 3002-11.
31. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011;121:3100-8.
32. Hu J, Kinn J, Zirakzadeh AA, Sherif A, Norstedt G, Wikström AC, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol 2013;172:490-9.